5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study

por Hecht, J Randolph, Mitchell, Edith P, Yoshino, Takayuki, Welslau, Manfred, Lin, Xun, Chow Maneval, Edna, Paolini, Jolanda, Lechuga, Maria Jose, Kretzschmar, Albrecht
Publicado 2015

Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib

por Harmon, Charles S, DePrimo, Samuel E, Raymond, Eric, Cheng, Ann-Lii, Boucher, Eveline, Douillard, Jean-Yves, Lim, Ho Y, Kim, Jun S, Lechuga, Maria José, Lanzalone, Silvana, Lin, Xun, Faivre, Sandrine
Publicado 2011

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors

por Michaelson, M. Dror, Gupta, Shilpa, Agarwal, Neeraj, Szmulewitz, Russell, Powles, Thomas, Pili, Roberto, Bruce, Justine Yang, Vaishampayan, Ulka, Larkin, James, Rosbrook, Brad, Wang, Erjian, Murphy, Danielle, Wang, Panpan, Lechuga, Maria Josè, Valota, Olga, Shepard, Dale R.
Publicado 2019

Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial

por Reichardt, Peter, Demetri, George D., Gelderblom, Hans, Rutkowski, Piotr, Im, Seock-Ah, Gupta, Sudeep, Kang, Yoon-Koo, Schöffski, Patrick, Schuette, Jochen, Soulières, Denis, Blay, Jean-Yves, Goldstein, David, Fly, Kolette, Huang, Xin, Corsaro, Massimo, Lechuga, Maria Jose, Martini, Jean-Francois, Heinrich, Michael C.
Publicado 2016